Navigation Links
USC research IDs potential treatment for deadly, HIV-related blood cancer
Date:6/25/2013

LOS ANGELES Researchers at the USC Norris Comprehensive Cancer Center have discovered a promising new way to treat a rare and aggressive blood cancer most commonly found in people infected with HIV.

The USC team shows that a class of drugs called BET bromodomain inhibitors effectively targets primary effusion lymphoma (PEL), a type of cancer for which those drugs were not expected to be effective.

"It's a reversal of the paradigm," said Preet Chaudhary, MD, PhD, chief of the Nohl Division of Hematology and Blood Diseases at the Keck School of Medicine of USC and principal investigator of the study. "Our results suggest that this new class of drug may be an effective treatment for a wider range of cancers than previously thought."

PEL is caused by infection with Kaposi's sarcoma-associated herpes virus, the most common cause of cancer among patients with AIDS. The prognosis for PEL is poor, with a median survival of three to six months. Thus, there is a critical need for new therapies for the disease.

Chaudhary and his colleagues show that inhibitors targeting the BRD4 protein blocked growth of PEL cells in a test tube and in a mouse model. The results were surprising because BET inhibitors were thought to be only effective against cancers linked to an overexpression of the Myc gene.

"We actually found that cancers that overexpress Myc are not as responsive to BRD4 inhibitors. PEL is more responsive," Chaudhary said.

Cancers like multiple myeloma and Burkitt's lymphoma overexpress the Myc gene and have been shown to respond to BRD4 inhibitors. In PEL, the Myc gene is moderately expressed and there is no chromosomal translocation as is seen in multiple myeloma or Burkitt's.

More research is needed to create compounds ready for testing in people. Once those drugs are ready for clinical trial, data from this study suggest that they may treat a wide range of cancers. Chaudhary anticipates testing them alone and in combination with other drugs.


'/>"/>

Contact: Alison Trinidad
alison.trinidad@usc.edu
323-442-3941
University of Southern California - Health Sciences
Source:Eurekalert

Related medicine news :

1. MS researchers determine that brain reserve independently protects against cognitive decline in MS
2. New screening approach identifies small proteins unique to melanoma cells, Moffitt researcher says
3. American Brain Tumor Association’s 2013 Patient & Family Conference Highlights Emerging Research
4. Voices Against Brain Cancer Comments on Recent Discovery in Ongoing Brain Cancer Research
5. Ethanol Leads Renewable Chemicals Market; Polymers Sector 14.3% CAGR Growth Forecasted by 2018 Says New Research Report at ReportsnReports.com
6. Arthrex, Depuy Mitek, and Smith & Nephew Lead the $1.5 Billion U.S. Orthopedic Soft Tissue Market, Reports iData Research
7. Citrus, Banana and Other Fruit Growing in Australia Industry Market Research Report Now Updated by IBISWorld
8. Notre Dame and Harper researchers developing novel method to test for HPV and oral cancers
9. Going to synagogue is good for health and happiness, Baylor researcher finds
10. Consider a text for teen suicide prevention and intervention, research suggests
11. America will never be gay and lesbian friendly, says researcher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... , ... August 17, 2017 , ... A recent report ... the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines their ... 11 ruling. , Presented as part of the Beckman Coulter Life Sciences ...
(Date:8/16/2017)... Bethpage, NY (PRWEB) , ... August 16, 2017 , ... ... Kullen, Long Island’s original family-owned supermarket, has put together suggestions for enjoying the season ... new recipe or activity, everyone in the family can join in on the fun. ...
(Date:8/16/2017)... ... 16, 2017 , ... Blue Health Intelligence (BHI) announced today that ... Dr. Spiro brings over 30 years of clinical, healthcare IT, value-based care, and change ... solutions. , “I am thrilled to welcome Dr. Spiro to BHI,” said Swati ...
(Date:8/16/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... August 16, 2017 ... ... list of the fastest growing companies in the U.S. for the second year in ... shown strong growth over the past three years. , “To be on the list ...
(Date:8/16/2017)... FL (PRWEB) , ... August 16, 2017 , ... ... standardized product data and images announced today that it was acquired by Advantage ... Industry’s solution for product information. IX-ONE’s members include the industry’s leading suppliers, brokers, ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
(Date:8/7/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO ... as president, effective Aug. 7, 2017. ... pursue other interests and will serve as president emeritus during ... served us in multiple leadership roles since he joined Diplomat ... and has provided decisive, strategic leadership which continues to benefit ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
Breaking Medicine Technology: